ADRM1 as a Radioligand Therapy Target
ADRM1, ADRM1 26S proteasome ubiquitin receptor, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, ADRM1 staining is highest in thyroid cancer (100% of samples positive), head and neck cancer (100% of samples positive) and neuroendocrine tumors (100% of samples positive). Evidence on whether ADRM1 internalizes is mixed. Clinical status: Clinical-stage (up to phase 2, any modality).
Is ADRM1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ADRM1 expression in cancer
Protein expression of ADRM1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 1.00 | High | 100% |
| Head and Neck Cancer | 0.92 | High | 100% |
| Neuroendocrine Tumors | 0.92 | High | 100% |
| Testicular Cancer | 0.86 | High | 100% |
| Bladder Cancer | 0.85 | High | 100% |
| Skin Cancer | 0.78 | High | 100% |
| Colorectal Cancer | 0.78 | High | 100% |
| Melanoma | 0.75 | High | 92% |
| Ovarian Cancer | 0.72 | High | 100% |
| Pancreatic Cancer | 0.70 | High | 100% |
| Liver Cancer | 0.70 | High | 90% |
| Breast Cancer | 0.67 | High | 100% |
| Cervical Cancer | 0.67 | High | 100% |
| Prostate Cancer | 0.67 | High | 100% |
| Glioma | 0.67 | High | 100% |
| Endometrial Cancer | 0.64 | High | 83% |
| Kidney Cancer | 0.61 | High | 100% |
| Lung Cancer | 0.61 | High | 100% |
| Lymphoma | 0.61 | High | 91% |
| Gastric Cancer | 0.52 | High | 78% |
Is ADRM1 internalized?
Uncertain. Insufficient literature found.
ADRM1 clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for ADRM1 yet. Search ClinicalTrials.gov for ADRM1 trials.
ADRM1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ADRM1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ADRM1 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.44 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EPCAM · SSTR2 · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how ADRM1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.